The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With MDD

Pfizer

Status and phase: Completed; Phase 2

Conditions: Depressive Disorder, Major

Treatments: Drug: NMDA Antagonist, CP-101,606 (traxoprodil)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00163059

A1611006

Details and patient eligibility

About

To determine if the NMDA antagonist, CP-101,606, is effective for depression

Sex: All

Ages: 18 to 55 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Primary DSM-IV diagnosis of MDD

Exclusion criteria

• Subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind